In conclusion, the study demonstrates the real-world efficacy of PCSK9-mAb therapy in achieving sustained LDL-C reduction and reducing cardiovascular hospitalization rates, highlighting its role in managing high-risk dyslipidemia patients. This evidence concerns the gene PCSK9 and metabolic syndrome.